Skip To Main Content
Royana Singh on Muck Rack

Royana Singh

As seen in: Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Royana

Contact Royana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Using a web platform for equitable distribution of COVID-19 monoclonal antibodies: a case study in resource allocation

|
By Shusen Sun, Mika K. Hamer, Royana Singh
| Frontiers
1 Introduction In November 2020, the U.S. Department of Health and Human Services (HHS) notified states and territories of the impending emergency use authorization (EUA) and federal distribution of the first monoclonal antibody (mAb) outpatient therapy for COVID-19, bamlanivimab (1). Bamlanivimab and subsequent anti-SARS-CoV-2 mAbs have been found to be effective therapies to reduce the risk of progression to severe COVID-19 in high-risk patients by up to 89% (2–4).
Open in Who Shared Issue with article?
See all 1 articles